-
Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China
•
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the launch of its GuardantOMNI test, a 500-gene panel based on blood sample detection, alongside its previously introduced liquid biopsy product, Guardant360. This initiative aims to enhance the development of tumor-targeted drugs and immunotherapies in clinical…
-
Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics
•
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully completed its initial public offering (IPO) of 33.2 million shares on the Hong Kong Stock Exchange. The shares were priced at HKD 12.32 (USD 1.58) each, with net proceeds expected to reach HKD 83.9 million…
